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A B S T R A C T   
It is unclear how the tryptophan (TRP) breakdown pathway relates to the activated inflammatory state of pa-
tients with major depressive disorder (MDD). 
We determined in two different cohorts of patients with MDD (n = 281) and healthy controls (HCs) (n = 206) 
collected for the EU-MOODINFLAME project:  
a.) the monocyte expression levels of 5 key pro-inflammatory cytokine/chemokine genes (ICCGs), 
5 type I interferon stimulated genes (ISGs), and 4 kynurenine pathway (KP) enzyme genes (i.e. 
IDO-1, KMO, CCBL1/KAT II and CCBL2/KAT III) by standard q-PCR,  
b.) serum levels of TRP, 5-HTrp, 5-HIAA, KYN, KYNA, 3-HK, XA, PIC, and QUIN by LC-MS/MS and/ 
or HPLC, and calculated various TRP/KP metabolism ratios. 
We then correlated outcomes to each other, and to the clinical characteristics of patients. 
Abbreviations: MDD, major depressive disorder; ICCGs, pro-inflammatory cytokine/chemokine-related genes; IL-1β, interleukin 1 beta gene; CCL2, chemokine 
C–C motif ligand 2 gene; 5-HT, 5-hydroxytryptamine; TRP, tryptophan; KP, kynurenine pathway; KYN, kynurenine; CSF, cerebrospinal fluid; IDO, indoleamine 2,3- 
dioxygenase enzyme; IFN, interferon; 3-HK, 3-hydroxykynurenine; QUIN, quinolinic acid; KYNA, kynurenic acid; TNFAIP3, tumor necrosis factor alpha-induced 
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MxA gene; HCs, healthy controls; ISGs, type I interferon-stimulated genes; IDO-1, indoleamine 2,3-dioxygenase gene; pSS, primary Sjögren Syndrome; KMO, 
kynurenine 3-monooxygenase gene; CCBL/KAT, cysteine conjugate beta lyase cytoplasmic/kynurenine aminotransferase gene; TDO, 2,3-dioxygenase enzyme; DSM- 
IV-TR, Diagnostic and Statistical Manual of Mental Disorders (4e), text revision; M.I.N⋅I, Mini International Neuropsychiatric Interview; SCID-I, structured clinical 
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Both cohorts of patients differed clinically; patients of the Munich cohort (n = 50) were less overweight, less 
medicated, were less in the current episode and showed a higher HAM-D 17 score as compared with patients of 
the Muenster cohort (n = 231). 
An increased expression of ICCGs was found in the circulating monocytes of patients of both cohorts; this was 
in particular evident in the Munich cohort. In contrast, ISGs monocyte expression levels tended to be reduced 
(both cohorts). 
TRP serum levels were linked to the pro-inflammatory (ICCGs) monocyte state of patients; a decrease in TRP 
serum levels was found in the Munich cohort; TRP levels correlated negatively to patient’s HAM-D 17 score. 
Contrary to what expected, KYN serum levels were not increased in patients (both cohorts); and an increased 
KYN/TRP ratio was only found in the Munich patients (who showed the lowest TRP serum levels). IDO-1 
monocyte expression levels were decreased in patients (both cohorts) and negatively associated to their pro- 
inflammatory (ICCGs) monocyte state. Thus, a depletion of TRP via an ICCGs-inflammatory IDO activation is 
not likely in MDD. 
Downstream from KYN, and regarding compounds influencing glutamate receptors (GR), reduced serum levels 
of KYNA (NMDA-R antagonist), 3-HK (NMDA-R agonist), and XA (mGlu2/3 agonist) were found in patients of 
both cohorts; PIC serum levels (NMDA-R antagonist) were increased in patients of both cohorts. Reduced QUIN 
serum levels (NMDA-R agonist) were found in patients of the Muenster cohort,only. 3-HK levels correlated to the 
monocyte inflammatory ICCG state of patients. The ultimate effect on brain glutamate receptor triggering of this 
altered equilibrium between peripheral agonists and antagonists remains to be elucidated.   
1. Background 
With a lifetime prevalence of up to 8–12% (Smith, 2014), major 
depressive disorder (MDD) is considered as a leading cause of disability 
worldwide (WHO, 2020). In addition, it is associated with numerous 
somatic diseases (e.g. rheumatoid arthritis, obesity) (Clarke and Currie, 
2009; Preiss et al., 2013), increasing mortality rates. Importantly, MDD 
has been linked to an increased risk of suicidal behavior, acting as the 
major contributor to suicide deaths (Saxena and Fleischmann, 2014; 
WHO, 2020). However, understanding the exact pathogenesis of the 
disorder still remains challenging, making diagnosis, treatment strati-
fication of patients and new drug discovery, difficult. 
A growing body of evidence has suggested an involvement of an 
abnormal inflammatory response system in the pathogenesis of MDD. 
Altered immune cell functions and raised circulating concentrations of 
pro-inflammatory cytokines/chemokines have been repeatedly found in 
MDD (Müller et al., 1993; Connor and Leonard, 1998; Anisman and 
Merali, 2002; Mikova et al., 2001; Myint et al., 2005; Irwin and Miller, 
2007; Dantzer et al., 2008; Wang et al., 2019). In line with this, we 
previously reported on the expression of a specific inflammation-related 
gene signature in the circulating monocytes of two cohorts of patients 
with MDD (Carvalho et al., 2014; Grosse et al., 2015; Grosse et al., 
2016). In this signature, gene expression patterns formed two main 
clusters of strongly interrelated genes; one cluster was composed of a set 
of pro-inflammatory cytokine/chemokine-related genes (ICCGs), such as 
the interleukin (IL)1-beta gene (IL-1β), the IL-6, or the chemokine C–C 
motif ligand 2 gene (CCL20). In particular monocytes of the cohort of 
older patients with a severe and melancholic depression were charac-
terized by an overexpression in this cluster of inflammatory genes. These 
patients were also characterized by elevated serum levels of pro- 
inflammatory cytokines/chemokines, such as IL-6, IL-8 and/or CCL2 
(Weigelt et al., 2011; Carvalho et al., 2014; Grosse et al., 2015). 
Whilst a functional deficit in the neurotransmitter 5-hydroxytrypta-
mine (5-HT, also known as serotonin) has been classically mentioned 
as an important contributor to the pathogenesis of depression (Coopen 
and Doogan, 1988; Hamon and Blier, 2013), it is only in recent years 
that various theories have emerged to provide a mechanistic link be-
tween the altered inflammatory state of patients with MDD and neuronal 
functional abnormalities. One of these theories has focused on an 
inflammation-related enhanced breakdown of tryptophan (TRP) along 
the kynurenine pathway (KP) (Maes et al., 2011; Leonard and Maes, 
2012: Arnone et al., 2018). TRP can be metabolized into 5-HT via the 
serotonin pathway, or into kynurenine (KYN) via the KP (Fig. 1) which 
in fact acts as the major catabolic pathway for TRP in the body (Stone 
et al., 2013; O’Farrell and Harkin, 2017) (Fig. 1). 
An increased TRP-to-KYN breakdown ratio has repeatedly been 
found in the blood and cerebrospinal fluid (CSF) of individuals with 
depression (Maes et al., 1990; Quak et al., 2014; Baranyi et al., 2017), 
particularly in those at a high risk of suicide (Bradley et al., 2015; 
Bryleva and Brundin, 2017; Messaoud et al., 2019). Activation of the KP 
is mediated, − among other mechanisms-, through activation of one of 
its rate-limiting enzymes, indoleamine 2,3-dioxygenase (IDO) (Maes 
et al., 2011; Leonard and Maes, 2012; Schwarcz and Stone, 2017; 
Arnone et al., 2018). IDO is induced by pro-inflammatory stimuli such as 
interferon (IFN)-alpha and/or IL-2 (Raison et al., 2010; Leonard and 
Maes, 2012); thus, IDO activation in pro-inflammatory monocytes and/ 
or microglia has been suggested as a key pathogenic mechanism that 
could explain the link between pro-inflammatory immune cells, TRP 
depletion and characteristic brain 5-HT deficiencies in MDD (Myint 
et al., 2007; Schwarcz and Stone, 2017). KYN is further catabolized into 
various downstream neuroactive metabolites throughout two degrading 
arms, often referred to as the potentially neurotoxic and potentially 
neuroprotective arms of the KP (Fig. 1). An inflammation-related cata-
bolic imbalance between these two breakdown arms, i.e. an enhanced 
production of the potentially neurotoxic catabolites 3-hydroxykynure-
nine (3− HK) and/or quinolinic acid (QUIN) at the expense of the 
potentially neuroprotective catabolites kynurenic acid (KYNA) and/or 
picolinic acid (PIC) has also been proposed in MDD (Myint and Kim, 
2003; Myint et al., 2007). This hypothesis is supported by findings of 
decreased KYNA and increased 3-HK and QUIN concentrations in the 
serum/plasma of patients with MDD (Savitz et al., 2015; Doolin et al., 
2018). However, recent studies have found normal or even reduced 
serum/plasma levels of KYN and 3-HK in individuals with depression 
(Hughes et al., 2012; Wurfel et al., 2017), questioning the idea of an IDO 
activation and overproduction of potentially neurotoxic downstream 
metabolites in MDD. 
The aim of the present study was to investigate how the inflamma-
tory monocyte state of patients with MDD correlates to the breakdown of 
TRP to KYN, and of KYN to its potentially neurotoxic and neuro-
protective downstream products. 
First, we determined the monocyte expression levels of five charac-
teristic ICCGs (i.e. IL-1B, CCL20, IL-6, TNFAIP3 and CXCL2) (Vogels 
et al., 2017) and of five genes driven by type I IFNs (i.e. IFI44, IFI44L, 
IFIT3, LY6E and MX1) (Brkic et al., 2013) in two cohorts of patients with 
MDD and healthy controls (HCs) participating in the EU- 
MOODINFLAME study (FP7-HEALTH:222963). These type I 
interferon-stimulated genes (ISGs) have been shown to be positively 
correlated to indoleamine 2,3-dioxygenase gene (IDO-1) expression and 
to a higher serum KYN/TRP in patients with primary Sjögren Syndrome 
(pSS) (Maria et al., 2016), supporting the theory of an inflammation- 
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induced activation of the KP via IDO. 
We also determined the monocyte expression levels of four genes 
encoding important KP degrading enzymes (i.e. IDO-1, kynurenine 3- 
monooxygenase gene (KMO), cysteine conjugate beta lyase cyto-
plasmic/kynurenine aminotransferase genes (CCBL1/KAT I and CCBL2/ 
KAT III), as well as serum levels of various important TRP/KP metabo-
lites (TRP, 5-HTrp, 5-HIAA, KYN, KYNA, 3-HK, XA, PIC, QUIN). 
In addition, the activity of the different KP enzymes was assessed by 
determining various KP metabolite ratios (e.g. the KYN/TRP ratio esti-
mating IDO and/or tryptophan 2,3-dioxygenase (TDO) enzyme activity; 
the KYNA/KYN ratio estimating KATs enzyme activities, the 3-HK/KYN 
ratio estimating KMO enzyme activity) (Fig. 1). 
Finally, the serum levels of the different TRP/KP metabolites and the 
different KP metabolite ratios were correlated to the monocyte ICCG and 
ISG inflammatory states, and to the monocyte expression levels of the 
four KP enzyme genes. 
2. Methods 
2.1. Study participants 
From 2010 to 2013, a total of n = 281 (aged 18–65 years) in- and 
outpatients with MDD were recruited from the Departments of Psychi-
atry at the University Hospital of Muenster, Germany (n = 231) and the 
University Hospital of the Ludwig Maximillian University in Munich, 
Germany (n = 50). 
Fig. 1. The tryptophan (TRP) catabolic pathway. The main branches are towards the serotonin pathway (5-HTrp, 5-HT and 5-H-IAA) and towards the potentially 
neuroprotective/neurotrophic (KYNA/PIC) and potentially neurotoxic (3-HK/QUIN) arms of the kynurenine pathway. Along the arrows, the main enzymes cata-
lyzing the reactions are given (i.e. TPH-II, MAO-L, IDO, TDO, KMO and KATs). 
Abbreviations: TRP: tryptophan; 5-HTrp: 5-hydroxytryptophan; 5-HT: 5-hydroxytryptamine; 5-HIAA: 5-hydroxyindoleacetic acid; KYN: kynurenine; KYNA: kynurenic 
acid; 3-HK: 3-hydroxykinurenine; XA: xanthurenic acid; 3-HAA: 3-hydroxyanthranilic acid; QUIN: quinolinic acid; PIC: picolinic acid; TPH-II: tryptophan hydrox-
ylase; MAO-L: monoamine oxidase; TDO: tryptophan 2,3-dioxygenase enzyme; IDO: indoleamine 2,3-dioxygenase enzyme; KMO: kynurenine 3-monooxygenase 
enzyme; KATs: kynurenine aminotransferase enzymes; NMDA-R: N-methyl-D-aspartate receptor; mGlu-R: metabotropic glutamate receptors; NAD+: nicotinamide 
adenine dinucleotide coenzyme. TRP breaks down to either 5-HT or KYN depending on IDO and/or TDO enzyme activity. KYN then breaks down towards KYNA 
(NMDA-R antagonist) or 3-HK (NMDA-R agonist) depending on KATs or KMO enzyme activities, respectively. 3-HK break downs to 3-HAA, which further breaks 
down to the potentially neuroprotective PIC, or to the potentially neurotoxic QUIN. PIC acts as an NMDA-R antagonist, while QUIN acts as an NMDA-R agonist, 
inducing excitotoxicity and neuronal death. QUIN (as 3-HK) is in addition a source of NAD+, playing a role in provision of energy. Interestingly, 3-HK is also able to 
break down to XA, which acts as an mGlu2R/mGlu3-R agonist, blocking excitotoxicity and neuronal death. 
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In the EU-MOODINFLAME study, all patients were diagnosed ac-
cording to the Diagnostic and Statistical Manual of Mental Disorders 
(4e), Text Revision (DSM-IV-TR) (American Psychiatric Association, 
2000). 
In Muenster cohort, the diagnosis was confirmed by the Mini- 
International Neuropsychiatric Interview (M.I.N.I) (Sheehan et al., 
1998), while in the Munich cohort, the diagnosis was confirmed by the 
Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First 
and Pincus, 1999). 
Severity of depression was assessed with the Inventory of Depressive 
Symptomatology, clinician-rated version (IDS-C) (Rush et al., 1986) (in 
the case of the Muenster cohort), and with the Hamilton Rating Scale for 
Depression, 17-item-version (HAM-D 17) (Hamilton, 1960) (in the case 
of the Munich cohort). All assessments were performed by two inde-
pendent experienced clinical psychiatrists. 
Excluded were patients who were unable to write or give informed 
consent, patients at immediate risk for suicidal behavior, and those who 
had another Axis I and II disorder. With the aim of homogenizing the 
sample, we decided not to include patients with MDD and psychotic 
symptoms, since it is discussed that psychotic depression has a different 
form of nosology than non-psychotic depression (Park et al., 2015). 
Patients had to be free of any obvious major medical illness in their 
medical history (i.e. cardiovascular, gastrointestinal, respiratory, 
neurologic, hepatic, renal, neurologic, infectious, immune or inflam-
matory diseases as well as untreated metabolic disorders) and also of any 
minor medical illness, including allergic reactions or infections, in the 4 
weeks before blood withdrawal. Excluded were also patients with any 
clinically significant physical findings (e.g. uncontrolled high blood 
pressure, claudication, heart murmurs, abnormal reflexes, etc.) or lab-
oratory results (e.g. abnormal glucose, liver and kidney values, etc.), as 
were women who were pregnant or breastfeeding. Recent (≤ 4 weeks) 
vaccinations were not allowed and patients taking immune-modulatory 
medication were excluded, too. 
Only in the case of the Munich cohort, and since this cohort was used 
for a study on the antidepressants effects of cyclooxygenase-2 (COX-2) 
inhibitors in patients with MDD (Arteaga-Henríquez et al., 2019), the 
use of antidepressant drugs (apart from benzodiazepines/analogues) 
was prohibited; patients treated with monoamine-oxidase inhibitors 
during the last 14 days or with fluoxetine during the last 6 weeks were 
also excluded, as were patients currently taking warfarin or pain med-
ications within 72 h prior to study entry. The Muenster patients used a 
variety of antidepressant and psychotropic drugs (Table 1). 
HCs (n = 206) were recruited from the same communities as the 
patients. The inclusion criteria for HCs were the absence of major Axis I 
disorders according to DSM-IV-TR criteria; no use of antidepressants or 
other psychotropic drugs was allowed. Furthermore, HCs had to be in 
self-proclaimed good health and free of any obvious medical illness, 
including infections and allergic reactions, for at least 4 weeks before 
blood withdrawal. 
The study was approved by the ethics committee of the Medical 
Association Westphalia-Lippe, Germany (2009-019-f-S) and the ethics 
committee of the medical faculty at the Ludwig Maximillian University 
of Munich, Germany (234–09). All participants provided written 
informed consent. 
2.2. Laboratory assessments 
All laboratory assays were centralized in the EU-MOODINFLAME 
study. Monocyte gene expression levels were measured by the Depart-
ment of Immunology, Erasmus Medical Center (Rotterdam, the 
Netherlands), TRP/KP metabolites by the Institute of Laboratory Medi-
cine, Medical Center of the Ludwig-Maximilian-University (Munich, 
Germany). 
2.2.1. Determination of the inflammatory activation state of circulating 
monocytes 
Details have been given in previous publications (Carvalho et al., 
2014; Grosse et al., 2015; Vogels et al., 2017), and only a synopsis of the 
methodology is given here. Blood was collected in sodium heparin tubes 
(36 ml) for immune cell preparation. From the heparinized blood, we 
prepared peripheral blood mononuclear cells (PBMCs) suspensions by 
low-density gradient centrifugation with Ficoll-Paque PLUS (GE 
Healthcare, Uppsala, Sweden) within 8 h to avoid erythrophagy-related 
activation of monocytes, as described previously in detail (Drexhage 
et al.,2010). PBMCs were then frozen in 10% dimethylsulfoxide and 
stored in liquid nitrogen. This enabled us to test the immune cells of 
patients and HCs together at a later stage at the Erasmus MC. CD14+
monocytes were isolated from aliquots of frozen PBMCs (from approx-
imately 20 ml of blood) by a magnetic cell sorting system (auto MACS 
Pro; Milteny Biotec, B.V., Bergisch Gladbach, Germany). The man 
viability was 86.3 ± 10.4 (Trypan blue staining); purity of monocytes, 
95.1 ± 3.0% (flow cytometry). mRNA was isolated from the purified 
CD14+ monocytes with an RNA easy mini-kit in accordance with man-
ufacturer’s instructions (Qiagen, Hilden, Germany). The mean monocyte 
yield after isolation was 2.0 ± 1.6 × 106/participant; the mean quantity 
of mRNA in monocytes was 3.2 ± 1.8 μg. One μg of mRNA was reverse 
transcribed by a high-capacity reverse transcription kit (Applied Bio-
systems, Foster City, CA, USA) to produce complementary deoxy-
ribonucleic acid (cDNA) for quantitative polymerase chain reaction 
(qPCR) (Taqman Arrays, format 48, Applied Biosystems, Foster City, CA, 
USA). qPCR was performed according to the manufacture’s protocol and 
validated against the single real-time (RT)-qPCR method. Per fill port, 
400 ng of cDNA was loaded. PCR amplification was performed with an 
Applied Biosystems Prism 7900HT sequence detection system with 
TaqMan Array block. Thermal cycler conditions were 2 min at 50 ◦C, 10 
min at 94.5 ◦C, 30 s at 97 ◦C, and 1 min at 59.7 ◦C for 40 cycles. For our 
study, we determined five top ICCGs (i.e. IL-1β, CCL20, IL-6, TNFAIP3 
and CXCL2) as determined in the study of Vogels et al. (2017) (Sup-
plementary Fig. 1). We verified -by using principle component analysis-, 
that these genes were indeed also belonging to the top ICCGs in the 
present study (Supplementary Fig. 2). Also in the most recent study on 
monocyte gene expression levels in a large cohort patients with MDD 
Table 1 
Clinical and demographic data of patients with MDD of the Muenster and 







M(SD) M(SD) p 
Number of previous 
depressive episodes 
3.62(6.01) 1.96(1.37) 0.058 





HAM-D 17 score 18.00(5.39) 24.46(2.48) <0.001 
Age (years) 40.14(12.62) 39.64 
(11.61) 
0.795 
bmi (kg/m2) 26.28(4.60) 23.40(3.16) <0.001    
n (%) n (%) p 
Sex   0.274 
Males 96(41.60) 25(50.0) 
Females 135(58.40) 25(50.0) 
Smoking   0.638 
Yes 105(45.70) 21(42.00) 
No 125(54.30) 29(58.00) 
Medication   <0.001 
Yes 223(96.50) 38(76.00) 
No 8(3.50) 12(24.00) 
ECT   0.020 
Yes 23(10.0) 0(0.00) 
No 208(90.0) 50(100.00) 
Values marked in bold indicate a p-value ≤0.05. Abbreviations: M: mean; SD: 
standard deviation; HAM-D 17: Hamilton Rating Scale for Depression, 17-item 
version; bmi: body mass index; ECT: electroconvulsive therapy. 
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(Schiweck et al., 2020), these genes belonged to the ICCGs signature 
(Supplementary Fig. 3). 
In addition, we determined five key type I ISGs (i.e. IFI44, IFI44L, 
IFIT3, LY6E, and MX1) of the study of Brkic et al. (2013) and Maria et al. 
(2016), and four important KP enzyme genes (i.e. IDO-1, KMO, CCBL1/ 
KAT I and CCBL2/KAT III). The expression of these 14 genes was 
normalized by the value of the housekeeping gene ABL1 and calculated 
by the comparative threshold cycle (CT) method. ABL1 has been found 
as being superior to other housekeeping genes for leukocyte gene level 
determination (Beillard et al., 2003). 
2.2.2. Determination of TRP/KP metabolite serum levels 
All serum samples were collected from fasting, early morning (8 a. 
m.-11 a.m.) venous blood samples, and immediately centrifuged, ali-
quoted and stored at − 80 ◦C. TRP, 5-hydroxytryptophan (5-HTrp), 5- 
hydroxyindoleacetic acid (5-HIAA), KYN, KYNA, 3-HK, xanthurenic acid 
(XA), QUIN and picolinic acid (PIC) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). The internal standards KYNA-D5, PIC-D4 and TRP- 
D5 were purchased from CDN Isotopes (Pointe-Claire, QC, Canada), and 
KYN-D4 was purchased from Buchem BV (Minden, the Netherlands). 
Reagents for protein precipitation, derivatization, and chromatography 
were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Biosolve 
(Valkenswaard, NL). Standards and a low- and high-quality control were 
established by adding defined amounts of each analyte to human serum 
samples obtained from a blood bank. The human serum was necessary 
because we had to take matrix effects into account to cover concentra-
tions below the analyte concentrations present in healthy humans. The 
serum was diluted 1 + 1 with liquid chromatography-mass spectrometry 
(LC-MS/MS)-grade water and used as the lowest calibrator. The values 
of this calibrator were calculated by standard addition. Because serum is 
not available without these analytes, there was no blank sample. A total 
volume of 300 μl serum samples, calibrators, and controls was used for 
sample preparation. 
2.2.2.1. HPLC method. In the Muenster cohort, TRP, 5-HIAA, KYN, 3- 
HK and KYNA (n = 207 MDD, 134 HC) serum levels were measured in 
a first set of determinations by a previously described high performance 
liquid chromatography (HPLC) method (Oades et al., 2010). In short, 
analytes were extracted from samples and calibrators/controls by using 
Waters Oasis MCX extraction cartridges (Waters Corporation, Milford, 
MA, USA). The eluent was then evaporated to dryness and reconstituted 
with 0.1 M phosphate buffered saline (PBS) for injection into the HPLC 
system. Analyses were carried out on a Waters 2695 chromatograph 
(Waters Corporation, Milford, MA, USA) with a 250 mm × 4 mm 
Supersphere 60 RP-select B, C8 column (Merck, Darmstadt, Germany), 
connected to a Waters 2487 dual-λ UV detector and a 2475 fluorescence 
detector. TRP (λex: 300 nm; λem: 350 nm) and 5-HIAA (λex: 300 nm; 
λem: 340 nm) were measured by fluorescence detection; KYN (365 nm), 
KYNA (330 nm) and 3-HK (365 nm) were measured by UV detection. 
2.2.2.2. LC-MS/MS method. In a second and third round of de-
terminations, serum levels of 5-HTrp, XA, QUIN and PIC (n = 157 MDD, 
n = 73 HC; Muenster cohort) and of TRP, 5-HTrp, 5-HIAA, KYN, 3-HK, 
KYNA, XA, QUIN and PIC (n = 47 MDD, 13 HC; Munich cohort) were 
analyzed by LC-MS/MS. The chromatographic system was composed on 
a Waters Acquity UPLC separation module connected to a Xevo TQ MS 
triple-quadrupole mass spectrometer with a Z-spray ESI ion source 
(Waters Corporation, Milford, MA, USA). Separation was performed on a 
Kinetex XB-C18, 2.6 μm, 2.1 × 150 mm column (Phenomenex, Torrance, 
CA, USA). Analytes were extracted by adding 50 μl of 2.0 M urea and 50 
μl of an internal standard solution containing KYN-D4, KYNA-D5, PIC- 
D4, and TRP-D5. Two precipitation steps were performed by adding 
200 μl methanol/ethanol (2/1 v: v) and then 800 μl acetonitrile. The 
supernatant was separated into two portions, which were evaporated 
separately. One of these portions was directly reconstituted in the 
mobile phase. The other portion was derivatized with 200 μl HCl/ 
butanol at 90 ◦C for 60 min and then, after evaporation, also recon-
stituted in the mobile phase. For chromatography, 7.5 μl of the recon-
stituted samples, calibrators, and controls were loaded onto the LC-MS/ 
MS system. QUIN and PIC were analyzed in the derivatized sample, 
while all other analytes were analyzed in the underivatized sample. For 
both derivatized and underivatized samples, gradient methods with a 
total duration of 7.5 min each were used for chromatographic separa-
tion. Mobile phase A was composed of 0.1% formic acid and 0.01% 
heptafluorobutyric acid in water; mobile phase B was methanol. The 
flow rate was set at 0.25 ml/min, and the column temperature was set at 
30.0 ◦C. Retention times for the analytes were between 3.1 and 6.0 min. 
The Xevo TQ MS was operating at atmospheric pressure, and electro-
spray ionization was in positive mode (ESI+). Ion source settings were as 
follows: capillary voltage, 1.00 kV; desolvation temperature, 650 ◦C; 
source temperature, 150 ◦C. Nitrogen was used as the desolvation gas, at 
an API gas flow rate of 1200 l/h, and argon was used as the collision gas, 
at a flow rate of 0.15 ml/min. The analytes and internal standards were 
detected by multiple reaction monitoring (MRM) technique. System 
operation, data acquisition, and data processing were controlled with 
MassLynx V4.1 software (Waters Corporation, Milford, MA, USA). The 
lower limit of quantification (LLOQ) and lower limit of detection (LLOD) 
of the method described above were calculated according to DIN 32645 
guidelines. The method was further validated based on the European 
Medicines Agency (EMEA) guidelines at the Institute of Laboratory 
Medicine, Medical Center of the Ludwig Maximilian University, Munich. 
2.3. Statistics 
Statistical analyses were performed with IBM SPSS v.21 and Micro-
soft Excel v.15.30 (170107) for Mac. Continuous sample characteristics 
are reported as mean (M) ± standard deviation (SD). Data were tested 
for normal distribution by the Shapiro-Wilk test (n < 30) and by the 
Kolmogorov-Smirnov test (n ≥ 30). For group comparisons of sample 
characteristics (e.g. MDD vs HCs), continuous data were analyzed with 
Mann-Whitney U tests; categorical data were analyzed with Pearson’s 
chi-square (χ2) tests. 
Since considerable differences were found between the Muenster and 
Munich patients regarding their clinical characteristics (disease acute-
ness, severity of current episode), as well as regarding their medication/ 
ECT state, we decided to do to two different analyses: First, we compared 
patients of the Muenster and Munich cohorts with their respective HCs, 
and then, we compared patients of both cohorts between themselves. 
Second, comparisons between the entire group of patients with MDD 
and HCs, and between the small subgroup of medication/ECT-naïve 
patients, and their respective HCs were also made. 
Group differences were tested by univariate analyses of covariance 
(ANCOVA), correcting for age, sex, bmi and smoking (patients vs. HCs), 
and for bmi, HAM-D 17 score, number of previous depressive episodes, 
durations of current episode, medication (yes/no), ECT (yes/no) 
(Muenster patients vs. Munich patients). In the case of medication/ECT- 
naïve subgroup of patients, we corrected only for smoking (yes/no). 
Bonferroni’s adjustments for multiple comparisons were additionally 
applied in all analyses. Correlations between were determined by 
Spearman’s-rank correlation coefficient (rho). All hypotheses were 
tested with α ≤ 0.05 (two-sided). 
Due to methodological differences, and in order to correct for site- 
dependent differences regarding monocyte gene expression levels and 
serum TRP/KP catabolite levels, we derived a fold change by dividing 
individual values of immune parameter or metabolite by the HC average 
value of each item per site (e.g. MDD individual value of site Muenster 
divided by HC average of site Muenster). This enabled us to pool the data 
of the two sites for the supplementary data (all patients together and all 
non-medicated patients of the two sites). The calculations of the values 
normalized to the HC values did not alter the fold differences (and sta-
tistical significances) between patients and HCs using the original data 
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per site (data not shown). 
3. Results 
3.1. Sample characteristics 
The clinical and demographic data of the study participants are 
shown in Table 1. In this table, all data are given per recruiting clinic 
(Muenster or Munich). 
3.1.1. Muenster cohort 
The MDD group included 96 men and 135 women with a mean age of 
40 years and a mean bmi of 26 kg/m2, indicating overweight. The IDS-C 
score was recorded in the 231 Muenster patients with MDD (see Section 
2.1); we calculated a HAM-D 17 correlate score from this IDS-C score as 
described in the literature (Rush et al., 1986; Trivedi et al., 2004). 
Table 1 shows that this resulted in a mean HAM-D 17 score of 18, 
indicating –in general-, cases with a moderate depression. Patients re-
ported a history of 4 previous depressive episodes on average; and being 
in the current episode since about 43 weeks. The vast majority of pa-
tients, i.e. 216 (93.5%) were on different regimens of antidepressants, 
139 (60.2%) were treated with benzodiazepines/analogues, 135 
(58.4%) were taking antipsychotic agents and/or mood stabilizers (15 
(6.5%)); 23(10%) patients were undergoing electroconvulsive therapy 
(ECT). 
3.1.2. Munich cohort 
The MDD group included 25 men and 25 women with a mean age of 
40 years and a mean bmi of 23 kg/m2, indicating a normal weight. The 
mean HAM-D 17 score was 25, indicating -in general-, cases with a se-
vere episode. Patients reported a history of 2 previous depressive epi-
sodes, and being in the current episode since 19 weeks; 38 (76%) were 
treated with benzodiazepines/analogues, the use of other psychotropic 
drugs/ECT was not allowed in the Munich patients (see Section 2.1). 
Taken together, patients of the Munich cohort were less overweight 
and less medicated as compared with patients of the Muenster cohort. 
They were also characterized by a more acute and severe depressive 
episode (Table 1). The Muenster cohort was characterized by a longer 
history of MDD, were also longer in the present episode; they were using 
extensively more medication, and had at the time of testing less severe 
depression (though still being depressed), they also had a significantly 
higher bmi. 
In Supplementary Table 3a, data are given for the entire group of 
patients with MDD (Muenster and Munich together, n = 281); in Sup-
plementary Table 3b, data are given separately for the patients without 
any form of medication (n = 20) (also not benzodiazepines/analogues, 
as was allowed in the less medicated Munich group). From the total 
group of HCs, we selected 20 age, sex and bmi-matched HCs to be 
compared to the subgroup of 20 medication/ECT-free patients (Sup-
plementary Table 3b). Where appropriate, we give immune and KP data 
for this subgroup underneath and in the supplementary material. 
3.2. Monocyte inflammatory state of patients with MDD and HCs 
Relative mRNA expression levels of ICCGs and ISGs of study partic-
ipants are shown in Fig. 2a,b. In these figures, the essential data are 
given per recruiting clinic. Supplementary Fig. 2a,c show data of the 
entire group of study participants, data of the subgroup of medication/ 
ECT-naïve patients and their respective HCs are given in Supplementary 
Fig. 2b,d. 
3.2.1. Relative mRNA expression levels of ICCGs in circulating monocytes 
The expression levels of five key ICCGs (i.e. IL-1β, IL-6, TNFAIP3, 
CCL20 and CXCL2) were determined in the circulating monocytes of 121 
patients with MDD (Muenster cohort (n = 81), Munich cohort (n = 40)), 
and in 124 HCs (Muenster cohort (n = 82), Munich cohort (n = 42)) 
(Fig. 2a). Fig. 2a shows a higher expression of ICCGs in patients with 
MDD of both the Muenster and the Munich cohorts as compared to their 
respective HCs. The same trend was found in the subgroup of medica-
tion/ECT-naïve patients (yet here, a statistical significance was however 
Fig. 2. a,b The relative mRNA expression levels of the indicated inflammatory genes in the circulating monocytes of patients with MDD and HCs. Gray bars represent 
the subgroup of patients with MDD, white bars represent the subgroup of HCs. Values are expressed as the fold change expression values relative to the mean value of 
the HC group (=1). *p ≤ 0.050, **p ≤ 0.005, ***p ≤ 0.001. Abbreviations: ICCGs: pro-inflammatory cytokine/chemokine genes; ISGs: type I interferon-stimulated 
genes; IL-1β: interleukin 1β gene; IL-6: interleukin 6 gene; TNFAIP3: tumor necrosis factor, alpha-induced protein 3 gene; CCL20: C-C-motif chemokine ligand 20 
gene; CXCL2: C-X-X-chemokine ligand 2 gene; IFI44: interferon-induced protein 44 gene; IFI44L: interferon-induced protein 44 Like gene; IFIT3: interferon-induced 
protein with tetratricopeptide Repeats 3 gene; LY6E: lymphocyte antigen 6 family member E gene; MX1: interferon-regulated resistance GTP-binding protein MxA 
gene. 
Compared to HCs, an increased expression of all ICCGs was found in patients of the Muenster cohort, values being statistically significant for IL-1β (F(1,157) = 4.022, 
p = 0.047,ηp2 = 0.025) and for CXCL2 (F(1,157) = 4.104,p = 0.044,ηp2 = 0.025). The same increase was found in patients of the Munich cohort, values being in this 
case significant for IL-1β (F(1,76)=4.411,p = 0.039,ηp2 = 0.055), IL-6 (F(1,76)=9.571,p = 0.003,ηp2 = 0.112), CCL2 (F(1,76)=5.299,p = 0.024,ηp2 = 0.065), and for 
CXCL2 (F(1,76)=8.375,p = 0.005,ηp2 = 0.099). On the contrary, patients were characterized by decreased in ISGs monocyte expression levels, a statistical signif-
icance was only reached for IFIT3 in the case of the Muenster cohort (F(1,103) = 6.598,p = 0.012,ηp2 = 0.060). No significant differences were found between 
patients of the Muenster and Munich cohorts in relation to their ICCGs and ISGs monocyte expression levels. 
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only reached for IL-6 (Supplementary Fig. 2b). The small number of 
subjects in this group probably plays a role here. 
Both the Muenster and Munich patients showed almost equally 
increased monocyte expression levels of the ICCGs (Fig. 2a). However, 
the increase was a little more outspoken in patients of the Munich 
cohort, showing statistical significant values in 4 of the 5 genes against 2 
of the 5 of the Muenster cohort when compared with HCs. Interestingly, 
a positive correlation was found between the monocyte expression levels 
of all top five ICCGs and patient’s HAM-D 17 score (being values sta-
tistically significant only for IL-6 (rho = 0.246, p = 0.006)). Significant 
correlations were not found between ICCGs monocyte expression levels 
and neither medication/ECT state, nor disease acuteness (data not 
shown). 
3.2.2. Relative mRNA expression levels of type I ISGs in circulating 
monocytes 
We also determined the expression levels of five key type I ISGs (i.e. 
IFI44, IFI44L, IFIT3, LY6E and MX1) in the circulating monocytes of 92 
patients with MDD (Muenster cohort (n = 52), Munich cohort (n = 40)), 
and 99 HCs (Muenster cohort (n = 57), Munich cohort (n = 42)) 
(Fig. 2b). Compared with HCs, patients with MDD of the two cohorts 
showed a reduced expression of all ISGs, yet a statistical significance was 
however only reached for IFIT3 in the subgroup of patients of the 
Muenster cohort (Fig. 2b). Also in the entire group of patients, ISGs were 
underexpressed compared to HCs (Supplementary Fig. 2c), the same 
trend was found in the subgroup of medication/ECT-naïve patients 
(Supplementary Fig. 2b). 
Supplementary Fig. 2b also shows that treatment state had no 
obvious effect on this slightly reduced expression of the ISGs in mono-
cytes. Significant correlations were not found between the monocyte 
expression levels of all ISGs and any of the clinical characteristics of 
patients (data not shown). 
3.3. Serum levels of TRP/KP metabolites, KP metabolism ratios and 
monocyte expression levels of KP enzymes genes in patients with MDD and 
HCs 
The TRP/KP catabolic data of study participants are shown in 
Figs. 3–7. In these figures, the essential data are given per recruiting 
clinic. Data of the entire group of patients and HCs, and the subgroup of 
medication/ECT-naïve patients and HCs are given in Supplementary 
Figs. 3–7. 
3.3.1. TRP to 5-HTrp and 5-HIAA breakdown pathway 
Compared with HCs, significantly decreased TRP and 5-HTrp serum 
levels were only found in the Munich patients (Fig. 3a,b); the same was 
found when compared with patients of the Muenster cohort. Considering 
the difference in treatment status between the Muenster and Munich 
patients, it is worthy to note that an effect of medication/ECT state was 
found for TRP and 5-HTrp in patients (i.e. not taking medication was 
significantly associated with lower TRP and 5-HTrp serum levels in 
patients (rho = 0.140, p = 0.026 and rho = 0.289, p < 0.001, respec-
tively)). In support of this, significantly reduced TRP and 5-HTrp serum 
levels were found in the subgroup of medication/ECT-naïve patients as 
compared to HCs (Supplementary Fig. 3b,d). In addition, a significant 
negative correlation was also found between TRP and 5-HTrp serum 
levels, and patient’s HAM-D 17 score (rho = − 0.279, p < 0.001 and rho 
= − 0.363, p < 0.001, respectively). 
Muenster patients with MDD showed lower 5-HIAA serum levels 
compared to HCs and to patients of the Munich cohort (Fig. 3c). In this 
case, significant correlations were however not found between 5-HIAA 
serum levels in patients, medication/ECT state and diseases severity/ 
acuteness (data not shown). 
3.3.2. TRP to KYN breakdown pathway 
Patients of both the Muenster and Munich cohorts showed reduced 
KYN serum levels towards HCs, though a statistical significance was not 
reached (Fig. 4a); a statistical significance was reached for the combined 
entire group of patients with MDD and HCs (Supplementary Fig. 4a). 
Both the Muenster and Munich patients equally contributed to the 
reduced KYN serum levels in patients (Fig. 4a). Accordingly, statistical 
significant correlations were not found between KYN serum levels and 
neither medication/ECT state, nor disease severity/acuteness (data not 
shown). 
Interestingly, a significantly higher KYN/TRP ratio was found only in 
patients of the Munich cohort when compared with their respective HCs, 
and with patients of the Muenster cohort (Fig. 4b), although this did not 
result in higher KYN serum levels (since the precursor TRP was very low, 
see Section 3.3.1). A significant positive correlation was found between 
the KYN/TRP ratio and HAM-D17 score in MDD patients (rho = 0.141, p 
= 0.029). 
Since IDO is an important inflammation-induced enzyme for the 
Fig. 3. a–c. Serum levels of TRP,5-HTrp and 5-HIAA in patients with MDD and HCs. Gray bars represent the subgroup of patients with MDD, white bars represent the 
subgroup of HCs. Values are expressed as the fold change expression values relative to the mean value of the HC group (=1). *p ≤ 0.050, **p ≤ 0.005, ***p ≤ 0.001. 
Abbreviations: TRP: tryptophan; 5-HTrp: 5-hydroxytryptophan; 5-HIAA: 5-hydroxyindoleacetic acid. 
Patients of the Munich cohort were characterized by decreased TRP and 5-HTrp serum levels as compared with HCs (F(1,54)=20.105,p < 0.001,ηp2 = 0.271 and F 
(1,54)=122.455,p < 0.001,ηp2 = 0.694, respectively), and with patients of the Muenster cohort (F(1,246) = 32.480,p < 0.001,ηp2 = 0.117 and F(1,155) = 34.202,p 
< 0.001,ηp2 = 0.181,respectively). Patients of the Muenster cohort were characterized by decreased 5-HIAA serum levels as compared with HCs (F(1,314) = 28.589, 
p < 0.001,ηp2 = 0.083) and with patients of the Munich cohort (F(1,226) = 12.166,p = 0.001,ηp2 = 0.051). 
G. Arteaga-Henriquez et al.                                                                                                                                                                                                                   
Progress in Neuropsychopharmacology & Biological Psychiatry 107 (2021) 110226
8
conversion of TRP into KYN, we also determined the expression levels of 
IDO-1 in the circulating monocytes of 68 patients with MDD (Muenster 
cohort (n = 29), Munich cohort (n = 39) and 67 HCs (Muenster cohort 
(n = 25), Munich cohort (n = 43)) (Fig. 5). 
IDO-1 monocyte expression levels did not differ between patients and 
HCs of both cohorts (Fig. 5); a statistical significance was in this case also 
not reached for the combined entire group of patients with MDD and 
HCs (Supplementary Fig. 5a). Significant differences were also not found 
between the Muenster and Munich patients in relation to IDO-1 mono-
cyte expression levels (Fig. 5). 
Accordingly, significant correlations were not found between 
medication/ECT state, illness severity/acuteness and monocyte expres-
sion levels of IDO-1 in patients (data not shown). 
3.3.3. KYN to KYNA breakdown arm 
Significantly reduced serum levels of the NMDA-R antagonist KYNA, 
and KYNA/KYN ratios were found in both cohorts of patients with MDD 
(Fig. 6a,b). This was in particular evident in patients of the Muenster 
cohort (Fig. 6a,b). However, significant correlations were not found 
between these metabolite serum levels and neither medication/ECT 
state, nor disease severity/acuteness in patients (data not shown). 
Since KAT enzymes are involved in the KYN to KYNA breakdown, we 
also determined the expression levels of CCBL1/KAT I and CCBL2/KAT 
III in the circulating monocytes of 94 patients with MDD (Muenster 
cohort (n = 55), Munich cohort (n = 39)), and 103 HCs (Muenster cohort 
(n = 61), Munich cohort (n = 42)) (Fig. 5). 
Fig. 5 shows that – in accord with the reduced KYNA serum levels-, a 
reduced CCBL1/KAT I monocyte expression was found in patients with 
MDD of both cohorts, however, values did not reach statistical signifi-
cance. A statistical significance was only reached in the subgroup of 
medication/ECT-naïve patients (Supplementary Fig. 5b). 
In contrast, an increased expression of CCBL2/KAT III was found in 
both cohorts of patients with MDD as compared to HCs; a statistical 
significance was however only found in the subgroup of patients of the 
Muenster cohort (Fig. 5) and in the entire group of patients with MDD 
(Supplementary Fig. 5a), in the latter irrespective of medication/ECT 
state (Supplementary Fig. 5b). Significant correlations were not found 
between CCBL1/KAT I and CCBL2/KAT III monocyte expression levels 
and neither medication/ECT state, nor disease severity in patients. 
3.3.4. KYN to 3-HK breakdown arm 
Compared to HCs, reduced serum levels of the NMDA-R agonist 3-HK 
(Fig. 6c), and a reduced 3-HK/KYN ratio were found in patients of both 
the Muenster and Munich cohorts (Fig. 6d). This was in particular 
evident in patients of the Munich cohort (Fig. 6c,d). Medication/ECT- 
naïve patients were also characterized by a decrease in serum levels of 3- 
HK (Supplementary Fig. 6d) and by a reduced 3-HK/KYN ratio (Sup-
plementary Fig. 6f) as compared to their respective HCs. Accordingly, a 
significant negative correlation was found between 3-HK serum levels, 
the 3-HK/KYN ratio, and patient’s HAM-D 17 score (rho = − 0.144, p =
0.028 and rho = − 0.142, p = 0.030, respectively). Not taking medication 
was also associated with lower 3-HK serum levels (rho = 0.179, p =
Fig. 4. a,b. Serum levels of KYN and the KYN/TRP ratio in patients with MDD and HCs. Gray bars represent the subgroup of patients with MDD, white bars represent 
the subgroup of HCs. Values are expressed as the fold change expression values relative to the mean value of the HC group (=1). *p ≤ 0.050, **p ≤ 0.005, ***p ≤
0.001. Abbreviations: KYN: kynurenine; TRP: tryptophan. 
Significant differences were not found between patients and HCs of both cohorts regarding KYN serum levels. Interestingly, patients of the Munich cohort were 
characterized by an increased KYN/TRP ratio as compared with their respective HCs (F(1,54)=7.940,p = 0.007,ηp2 = 0.128) and with patients of the Muenster cohort 
(F(1,228) = 19.059,p < 0.001,ηp2 = 0.077). 
Fig. 5. The relative mRNA expression levels of the indicated inflammatory KP 
enzyme genes in the circulating monocytes of patients with MDD and HCs. Gray 
bars represent the group of patients with MDD, white bars represent the group 
of HCs. Values are expressed as the fold change expression values relative to the 
mean value of the HC group (=1). *p ≤ 0.050, **p ≤ 0.005, ***p ≤ 0.001. 
Abbreviations: IDO-1: indoleamine 2,3-dioxygenase gene; KMO: kynurenine 3- 
monooxygenase gene; CCBL1/KAT I: cysteine conjugate beta lyase cyto-
plasmic1/kynurenine aminotransferase I gene; CCBL2/KAT III: cysteine conju-
gate beta lyase cytoplasmic 2/kynurenine aminotransferase III gene. 
Significantly decreased KMO monocyte expression levels were found in patients 
of the Munich cohort as compared with HCs (F(1,75)=6.865,p = 0.011,ηp2 =
0.084), and with patients of the Muenster cohort (F(1,60)=9.420,p = 0.003,ηp2 
= 0.136). Significantly increased expression levels of CCBL2/KAT III were 
found in the circulating monocytes of patients of the Muenster cohort as 
compared with HCs (F(1,109) = 7.414,p = 0.008,ηp2 = 0.064). 
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Fig. 6. a–e. Serum levels of the indicated KP metabolites and KP metabolism ratios in patients with MDD and HCs of both the Muenster and Munich cohorts. Gray 
bars represent the subgroup of patients with MDD, white bars represent the subgroup of HCs. Values are expressed as the fold change expression values relative to the 
mean value of the HC group (=1). *p ≤ 0.050, **p ≤ 0.005, ***p ≤ 0.001. Abbreviations: KYNA: kynurenic acid; KYN: kynurenine. 
Decreased KYNA serum levels and a decreased KYNA/KYN ratio were found in both cohorts of patients with MDD as compared with HCs. This was in particular 
evident in patients of the Muenster cohort, showing decreased KYNA serum levels (F(1,240) = 5.333,p = 0.022,ηp2 = 0.022), and a decreased KYNA/KYN ratio as 
compared with patients of the Muenster cohort (F(1,225) = 5.900,p = 0.016,ηp2 = 0.026). Decreased 3-HK serum levels, and a reduced 3-HK/KYN ratio were also 
found in both cohorts of patients with MDD. In this case, this was in particular evident in patients of the Munich cohort, showing significantly decreased 3-HK serum 
levels (F(1,223) = 14.235,p < 0.001,ηp2 = 0.060) and a decreased 3-HK/KYN ratio (F(1,223) = 22.845,p < 0.001,ηp2 = 0.093) as compared with patients of the 
Muenster cohort. 
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0.006) and with a reduced 3-HK/KYN ratio in patients (rho = 0.165, p =
0.012). 
Since KMO is the enzyme involved in the KYN to 3-HK transition 
(Fig. 1), KMO expression levels were also determined in the circulating 
monocytes of 68 patients with MDD (Muenster cohort (n = 29), Munich 
cohort (n = 25)) and 67 HCs (Muenster cohort (n = 39), Munich cohort 
(n = 42)) (Fig. 5). Compared to HCs, KMO was significantly underex-
pressed in the circulating monocytes of the Munich patients, but not of 
the Muenster patients (Fig. 5). The same trend was found in the sub-
group of medication/ECT-naïve patients (Supplementary Fig. 5b). We 
also found a significant negative correlation between KMO monocyte 
expression levels and patient’s HAM-D 17 score (rho = − 0.357, p =
0.003). 
Since both 3-HK and KYNA serum levels were reduced in both co-
horts of patients with MDD, we also determined the KYNA/3-HK ratio, in 
order to get an idea of the relative overweight of the potential neuro-
protective over the potential neurotoxic arms of the KP. Fig. 6e inter-
estingly shows a difference between Muenster and Munich patients 
regarding the KYNA/3-HK ratio; while in Muenster patients the poten-
tial neurotoxic arm was favored in comparison to HCs, the Munich pa-
tients showed an overweight of the potential neuroprotective arm. It 
must again be stressed here that in both cohorts, levels of 3-HK and 
KYNA were actually reduced. 
3.3.5. 3-HK to XA breakdown arm 
Compared to HCs, significantly decreased XA serum levels were 
found in patients of both the Muenster and Munich cohorts (Fig. 7a). 
Also in the entire group, XA serum levels were significantly decreased in 
patients as compared to HCs (Supplementary Fig. 7a), this irrespective of 
the medication/ECT state (Supplementary Fig. 7b). Accordingly, sig-
nificant correlations were neither found between XA serum levels and 
medication/ECT status, nor with disease severity/acuteness in patients 
(data not shown). 
3.3.6. 3-HK to PIC breakdown arm 
Significantly increased PIC serum levels were found in patients of 
both the Muenster and Munich cohorts as compared to their respective 
HCs (Fig. 7b). Also in the entire group, PIC serum levels were signifi-
cantly increased as compared to HCs (Supplementary Fig. 7c), the same 
trend was found in the subgroup of medicated/ECT patients (Supple-
mentary Fig. 7d, p = 0.053). Accordingly, significant correlations were 
not found between PIC serum levels and neither medication/ECT status, 
Fig. 7. a–d. Serum levels of the indicated KP downstream catabolites and the KYNA/QUIN ratio in patients with MDD and HCs. Gray bars represent the group of 
patients with MDD, white bars represent the group of HCs. Values are expressed as the fold change expression values relative to the mean value of the HC group (=1). 
*p ≤ 0.050, **p ≤ 0.005, ***p ≤ 0.001. Abbreviations: MDD: major depressive disorder; HC: healthy controls; XA: xanthurenic acid; QUIN: quinolinic acid; PIC: 
picolinic acid; KYNA: kynurenic acid. Compared with HCs, patients with MDD of both cohorts showed reduced serum levels of the mGlu2/3 agonist XA ((F(1,211) =
41.437,p < 0.001,ηp2 = 0.164 (Muenster cohort) and F(1,54)=8.408,p = 0.005,ηp2 = 0.135 (Munich cohort)). Significant differences were not found between 
patients of both the Muenster and Munich cohorts in relation to their XA serum levels. On the contrary, patients with MDD of both cohorts were characterized by 
increased serum levels of the potentially NMDA-R antagonist PIC ((F(1,201) = 8.593,p = 0.004,ηp2 = 0.041 (Muenster cohort) and F(1,52)=10.926,p = 0.002,ηp2 =
0.174 (Munich cohort)). Both the Muenster and Munich patients equally contributed to the reduced XA, and increased PIC serum levels in patients. Interestingly, 
patients of the Muenster cohort were characterized by significantly decreased serum levels of the NMDA-R agonist QUIN as compared with HCs (F(1,223) = 7.647,p 
= 0.006,ηp2 = 0.033) and with patients of the Munich cohort (F(1,194) = 6.860,p = 0.010,ηp2 = 0.034). 
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nor disease severity/acuteness (data not shown). 
3.3.7. 3-HK to QUIN breakdown arm 
Interestingly, patients of the Muenster cohort were characterized by 
significantly reduced QUIN serum levels as compared to their respective 
HCs, and to patients of the Munich cohort (Fig. 7c). However, significant 
correlations were not found between QUIN serum levels and neither 
medication/ECT status, nor with disease severity/acuteness (data not 
shown). 
To investigate in more detail the apportioning of the so-called 
potentially neuroprotective versus potentially neurotoxic KP catabo-
lites, we also analyzed the KYNA/QUIN ratio (Fig. 7d). Compared to 
HCs, this neuroprotective over neurotoxic ratio was found decreased in 
patients of both the Muenster and Munich cohorts, however, a statistical 
significance was not reached (Fig. 7d). A statistical significance was only 
reached if all patients were taken together (Supplementary Fig. 7g). 
3.4. Correlations between the monocyte expression levels of pro- 
inflammatory genes and the monocyte expression levels of KP enzyme 
genes in patients with MDD 
First, it is worthy to note that significant and negative correlations 
were found between the increased expression of ICCGs in patient’s 
monocytes, and the monocyte expression levels of the 4 KP enzyme 
genes in patients (Table 2). This was in particular evident for KMO 
(catalyzing the transition of KYN to 3-HK), CCBL1/KAT I and CCBL2/ 
KAT III (catalyzing the transition of KYN to KYNA). In contrast, a sig-
nificant positive correlation was found between the monocyte expres-
sion levels of IDO-1 and the monocyte expression levels of 4/5 ISGs in 
patients (Table 2), confirming the correlation data of Maria et al. (2016) 
in Sjögren’s disease. 
3.5. Correlations between the monocyte expression levels of pro- 
inflammatory genes and serum levels of TRP/KP metabolites and KP 
metabolite ratios in patients with MDD 
Table 3 shows that the higher the expression of ICCGs in patient’s 
monocytes, the lower the TRP serum levels in patients. In addition, a 
significant positive correlation was found between the monocyte 
expression levels of ICCGs and the KYN/TRP ratio. 
Table 3 additionally shows that the expression of ICCGs in patient’s 
monocytes significantly and negatively correlated to 3-HK serum levels 
and to the 3-HK/KYN ratio in patients. 
Noteworthy significant correlations were not found between the 
expression levels of ICCGs in patient’s monocytes and serum levels of 
KYN, KYNA, the KYNA/KYN ratio, XA, QUIN, PIC, and the KYNA/QUIN 
ratio in patients (data not shown). A consistent and noteworthy picture 
of correlations could also not be found for the monocyte expression 
levels of ISGs and any of the serum TRP/KP catabolites in patients. 
4. Discussion 
The TRP catabolic pathway in patients with MDD shows various 
activation and deactivation steps which are linked to their pro- 
inflammatory state. Table 4 gives an overview of the main data, we 
refer to Fig. 1 for the different TRP/KP catabolic pathways, and for the 
effects of TRP/KP metabolites on neuronal cell functions. 
4.1. Tryptophan to 5-HTrp and 5-HIAA breakdown pathway 
Consistent with previous findings (Maes et al., 1990; Charney, 1998; 
Hughes et al., 2012; Ogawa et al., 2014; Cowen and Browning, 2015; 
Kuwano et al., 2018), this study found reduced TRP and 5-HTrp serum 
levels in patients with MDD as compared to HCs, particularly in the more 
acute, severely affected and less medicated Munich patients with a 
relatively high monocyte ICCG expression. Indeed, the reduced TRP and 
5-HTrp serum levels were associated with higher HAM-D 17 scores, and 
a higher monocyte ICCG expression (only TRP serum levels). They were 
also evident in the medication/ECT-naïve patients of the combined co-
horts (Supplementary Fig. 3b,d). 
Reduced TRP serum levels are a well-known feature of MDD and are 
thought to play a role in at least, part of the depressive syndrome, since 
TRP is – via 5-HTrp -, the ground substance for 5-hydroxytryptamine (5- 
HT, also known as serotonin), an essential neurotransmitter in mood 
regulation (Lapin and Oxenkrug, 1969; Toker et al., 2010). 
Our data thus show a shortage of this ground substance particularly 
in non-medicated, severe and recent cases of MDD with a relatively high 
monocyte ICCG inflammatory state (the Munich cases), while this is was 
not the case in the medicated, longstanding and less severe cases of the 
Muenster cohort. Our observations thus support the important role of 
TRP and 5-HT deficiency in MDD, and a correcting effect of medication 
for this pathway. 
4.2. TRP to KYN breakdown pathway 
TRP is not only metabolized into 5-HT via the serotonin pathway, but 
also into KYN via the KP, which in fact acts as the major catabolic 
Table 2 
Correlations between the monocyte expression levels of ICCGs/ISGs and the 
monocyte expression levels of KP enzyme genes in patients with MDD.   
IDO-1 KMO CCBL1/KATI CCBL2/KATIII 
IL-1β − 0.137 0.016 ¡0.303** ¡0.369*** 
IL-6 − 0.175 ¡0.410** ¡0.319** ¡0.236* 
TNFAIP3 0.061 − 0.221 ¡0.207* − 0.010 
CCL20 ¡0.309* ¡0.372** ¡0.396*** ¡0.233* 
CXCL2 ¡0.337** ¡0.317** ¡0.290** ¡0.250* 
IFI44 0.404* 0.158 − 0.014 − 0.165 
IFI44L 0.430** 0.317* 0.071 0.124 
IFIT3 0.458** 0.306 0.161 − 0.028 
LY6E 0.229 0.088 − 0.304 0.148 
MX1 0.362* 0.187 0.174 0.010 
Significant correlations are marked with an asterisk (*p ≤ 0.050, **p ≤ 0.005, 
***p ≤ 0.001) and highlighted in bold. Abbreviations: IDO-1:indoleamine 2,3- 
dioxygenase gene; KMO: kynurenine 3-monoxygenase gene; CCBL1/KAT I: 
cysteine conjugate beta lyase cytoplasmic1/kynurenine aminotransferase I gene; 
CCBL2/KAT III: cysteine conjugate beta lyase cytoplasmic 2/kynurenine 
aminotransferase III gene; IL: interleukin; TNFAIP3: tumor necrosis factor, 
alpha-induced protein 3 gene; CCL20: C–C motif chemokine ligand 20 gene; 
CXCL2: C-X-X-chemokine ligand 2 gene; IFI: interferon-induced protein gene; 
LY6E: lymphocyte antigen 6 family member E gene; MX1: interferon-regulated 
resistance GTP-binding protein MxA gene. 
Table 3 
Correlations between the monocyte expression levels of ICCGs/ISGs, serum 
levels of TRP/KP metabolites and KP metabolite ratios in patients with MDD.   
TRP KYN/TRP 3-HK/KYN 3-HK 
IL-1β − 0.018 0.070 − 0.084 − 0.111 
IL-6 ¡0.220* 0.305** ¡0.420*** ¡0.319** 
TNFAIP3 ¡0.264** 0.314*** ¡0.442*** ¡0.282** 
CCL20 − 0.164 0.282** ¡0.334** ¡0.245* 
CXCL2 − 0.179 0.197* − 0.140 − 0.170 
IFI44 − 0.124 − 0.068 0.008 − 0.173 
IFI44L − 0.019 − 0.218 0.070 − 0.098 
IFIT3 − 0.055 − 0.167 0.179 − 0.006 
LY6E 0.082 0.031 − 0.286 − 0.222 
MX1 − 0.043 − 0.287 0.219 0.015 
Significant correlations are marked with an asterisk (*p ≤ 0.050, **p ≤ 0.005, 
***p ≤ 0.001) and highlighted in bold. Abbreviations: TRP: tryptophan; KYN: 
kynurenine; 3-HK: 3-hydroxykynurenine; IL: interleukin; TNFAIP3: tumor ne-
crosis factor, alpha-induced protein 3 gene; CCL20: C–C motif chemokine 
ligand 20 gene; CXCL2: C-X-X-chemokine ligand 2 gene; IFI: interferon-induced 
protein gene; LY6E: lymphocyte antigen 6 family member E gene; MX1: 
interferon-regulated resistance GTP-binding protein MxA gene. 
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pathway for TRP in the body (Stone et al., 2013; O’Farrell and Harkin, 
2017) (Fig. 1). 
In recent years, various theories have emerged to provide a mecha-
nistic link between the existence of an altered inflammatory state in 
patients with MDD and the decreased TRP availability for 5-HT synthesis 
in MDD. One of these theories has focused on an increased breakdown of 
TRP down the KP by activation of KP breakdown enzymes under the 
influence of inflammatory stimuli (Maes et al., 2011; Leonard and Maes, 
2012; Arnone et al., 2018). 
In support of such view, our study found an increased KYN/TRP 
ratio, but only in the subgroup of patients of the Munich cohort (char-
acterized by a more severe episode as compared with patients of the 
Muenster cohort). The increased KYN/TRP ratio was found positively 
associated with the pro-inflammatory (ICCGs) state of patient’s mono-
cytes. This is in accord with a higher entrance of TRP into the KP in the 
Munich patients with a high monocyte pro-inflammatory state, sup-
porting a view of TRP depletion down the KP at the expense of the se-
rotonin pathway. 
However, KYN serum levels (and many of the KYN downstream 
products) were not raised in the Munich patients. We therefore assume 
that it is not likely that there is a considerable drain of TRP down the KP 
in the Munich patients and that, initially reduced TRP levels (perhaps 
reduced by low uptake via the gut) may play a more important role in 
acting as factor for the raised KYN/TRP ratio. 
4.2.1. A prominent role for IDO in the TRP to KYN breakdown pathway in 
patients with MDD? 
IDO is one of the most well-known enzymes for the transition of TRP 
into KYN. It is specifically expressed in pro-inflammatory immune cells; 
therefore, a prominent role has been suggested for IDO in the phe-
nomenon of inflammation-induced increased TRP to KYN degradation. 
However, and against such a view of a prime role of IDO in depleting 
TRP levels in MDD, IDO-1 was not overexpressed in the otherwise pro- 
inflammatory activated monocytes of patients. In fact, a negative cor-
relation was found between the monocyte expression of ICCGs and IDO- 
1 in patient’s monocytes. Supporting our findings, Hughes et al. (2012) 
also found a strong TRP depletion, a high KYN/TRP ratio and normal 
KYN levels in the presence of a normal IDO-1 expression in subjects with 
MDD, also raising doubts about an activation of IDO in MDD. Other 
investigators have pointed to liver TDO, activated by stress, as playing a 
more prominent role in the TRP to KYN transition in patients with MDD 
(Dantzer et al., 2011; Maes et al., 2011; Badawy, 2013; Godoy et al., 
2018; Qin et al., 2018). However, as an increase in KYN serum levels was 
not observed in our study, it is unlikely that the depletion of TRP 
resulted from a stress-related increase in TDO activity. 
Interestingly, a positive correlation was found between the monocyte 
expression levels of IDO-1 and type I ISGs in patients, although the ISG 
expression was not raised (it was earlier suppressed). This positive 
correlation reinforces the idea that IDO is under the control of inflam-
mation, but of another type than the ICCG expression. Since ISG in-
flammatory overexpression is a characteristic of patients with systemic 
autoimmune conditions such as pSS (Maria et al., 2016), while ICCG 
inflammatory over expression is a characteristic of patients with mood 
disorders, our present and previous findings suggest that an increased 
IDO mediated TRP to KYN breakdown is particularly relevant for the 
immune dysregulation in systemic autoimmune conditions and not for 
that in mood disorders. This may be of relevance since it may distinguish 
the MDD state from the state of depression that occurs during the course 
of other somatic diseases such as pSS or from depression induced by 
administration of exogenous cytokines such as IFN-α (Capuron et al., 
2012; Raison et al., 2010). 
4.3. KYN to 3-HK and KYNA breakdown arms 
In the present study, and contrary to what expected (see Background 
section), significantly reduced 3-HK serum levels, and a significantly 
reduced 3-HK/KYN ratio (reflecting KMO enzyme activity) were found 
in both cohorts of patients with MDD as compared to HCs, although 
these phenomena were in particular pronounced in patients of the 
Munich cohort. The more reduced KMO activity in the Munich patients 
was reflected in a significantly reduced monocyte expression level of 
KMO. Since the expression of the ICCGs in patient’s monocytes were 
negatively associated with the monocyte expression level of KMO, the 3- 
HK/KYN ratio, and with the 3-HK serum levels, our findings suggest that 
the higher the pro-inflammatory ICCGs state of patient’s monocytes, the 
lower the potential of monocytes to catabolize KYN into 3-HK. Impor-
tantly, this decrease in the KYN to 3-HK transition was also negatively 
associated with a higher HAM-D 17 score in patients. 
In support of our findings, Wurfel et al., 2017 also found lower 3-HK 
serum levels in a cohort of patients with affective disorders (i.e. MDD, 
bipolar disorder and schizoaffective disorder), with 3-HK serum levels 
Table 4 
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TRP ↓ = Negative to 
ICCGs 
Negative 
5-HTrp ↓ = No correlation Negative 
KYN = = No correlation No correlation 





= = Negative to 
ICCGs 
No correlation 
Positive to ISGs 
KYNA ↓ ↓ No correlation No correlation 
KYNA/KYN 
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CCBL1/KAT I 
(monocytes) 





= ↑ Negative to 
ICCGs 
No correlation 
3-HK ↓ ↓ Negative to 
ICCGs 
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↑ ↓ Negative to 
ICCGs 
Positive 
XA ↓ ↓ No correlation No correlation 
PIC ↑ ↑ No correlation No correlation 
QUIN = ↓ No correlation No correlation 
KYNA/QUIN 
ratio 
= = No correlation No correlation 
↑: statistically significantly elevated compared to HCs, =: no statistically sig-
nificant differences between patients and HCs; ↓: statistically significantly 
decreased compared to HCs. Abbreviations: MDD: major depressive disorder; 
HAM-D 17: Hamilton Rating scale for depression, 17-item version; ICCGs: in-
flammatory cytokine/chemokine genes; ISGs: interferon stimulated genes; TRP: 
tryptophan; 5-HTrp: 5-Hydroxytryptophan; KYN: kynurenine; IDO-1: indole-
amine 2,3-dioxygenase gene; KYNA: kynurenic acid; CCBL1/KAT I: cysteine 
conjugate beta lyase cytoplasmic1/kynurenine aminotransferase I gene; CCBL2/ 
KAT III: cysteine conjugate beta lyase cytoplasmic 2/kynurenine aminotrans-
ferase II gene; 3-HK: 3-hydroxykynurenine; KMO: kynurenine 3-monooxygenase 
gene; XA: xanthurenic acid; PIC: picolinic acid; QUIN: quinolinic acid. 
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being particularly reduced in affective psychosis. In addition, the study 
of Clark et al., 2016 also found a reduced KP metabolism, be it not in the 
blood, but in the ventrolateral prefrontal cortex of individuals with 
depression. Hughes et al. (2012) on the other hand did neither find a 
deactivation nor an activation of the KP in depressed patients. 
With regard to the KYN to KYNA breakdown arm, reduced serum 
levels of KYNA, and a reduced KYNA/KYN ratio (reflecting a reduced 
activity of the KAT enzyme system) were found in patients of both co-
horts. With regard to the KAT enzymes involved in the breakdown of 
KYN to KYNA, a contrasting picture was found. In accord with a reduced 
activity of the KAT enzyme system, we found a tendency for a reduced 
expression of the CCBL1/KAT I in the circulating monocytes of patients 
of both cohorts (but only in the unmediated patients). However, there 
also was an overexpression of CCBL2/KAT III in the monocytes of the 
Muenster patients. We explain this inconsistency by assuming that 
monocyte CCBL2/KAT III must play a minor role in the systemic tran-
sition of KYN to KYNA in patients with MDD. Clearly more in-
vestigations are needed on the role of the three KAT enzymes in KYN-to- 
KYNA transition in different tissues. 
Collectively, our data suggest a deactivation of both the potentially 
neuroprotective KYN to KYNA, and the potentially neurotoxic KYN to 3- 
HK breakdown arms in MDD. However, consistent signs of an involve-
ment of the monocyte pro-inflammatory (ICCGs) state of patients was 
only found for the deactivation of the KYN to 3-HK breakdown arm. 
4.4. 3-HK to XA breakdown arm 
XA has been implicated in various central nervous system disorders 
such as chronic pain and/or epilepsy (Melnikova, 2003; Curto et al., 
2015). In addition, it has also been shown to exert antipsychotic effects 
and, interestingly, it has been reported as substantially reduced in pa-
tients with schizophrenia (Curto et al., 2019). However, only few studies 
have measured XA serum levels in MDD (Colle et al., 2020; Ryan et al., 
2020). Consistent with previous reports, reduced XA serum levels were 
found in both cohorts of patients with MDD as compared with HCs. This 
was irrespective of disease severity/acuteness, and of medication/ECT 
status. 
XA production is also under the influence of KAT enzymes. As dis-
cussed in 4.3, a reduced monocyte expression of CCBL1/KAT I, accom-
panied by an increased monocyte expression of CCBL2/KAT III were 
found in the circulating monocytes of –especially-, patients of the 
Muenster cohort (and the subgroup of medication/ECT naïve patients, 
see Supplementary Fig. 5b). We reiterate the need of further studies to 
understand the relationship between the chronic low grade inflamma-
tory state of patients with MDD, KATs expression, and XA production 
from 3-HK in MDD. 
Our results could be however of relevance due to XA’s capacity to 
activate metabotropic glutamate 2 and 3 (mGlu2/3) receptors and 
thereby, inhibit excitatory synaptic transmission (Fazio et al., 2015). In 
the last years, glutamatergic pathway disturbances have emerged as an 
important key factor in, at least, a subgroup of patients with MDD, and 
increasingly literature doubts about (a generalized) validity of the 
“serotonergic theory of MDD”, pointing in the direction that low sero-
tonin levels may be an important factor for preserving recovery from 
depression rather than having a primary effect on mood lowering in 
vulnerable people (Cowen, 2008; Cowen and Browning, 2015). There-
fore, modulation of glutamate receptors has been suggested as an 
important new target for the treatment of MDD (Matrisciano et al., 2007; 
Park et al., 2015). In line with this, recent evidence has showed 
antidepressant-like activity of mGlu2/3 receptor agonists in animal 
models of depression (Feinberg et al., 2002; Matrisciano et al., 2007). 
4.5. 3-HK to QUIN and PIC levels 
Increased serum levels of the NMDA-R antagonist PIC were found in 
patients of both cohorts as compared to their respective HCs; this 
increase was irrespective of disease severity/acuteness and of medica-
tion/ECT status. 
On the opposite, and contrary to what expected, significantly 
decreased serum levels of the NMDA-R agonist QUIN were found in 
patients of the Muenster cohort as compared with both HCs, and with 
patients of the Munich cohort. However, significant correlations were 
neither found between QUIN serum levels nor with disease severity/ 
acuteness or medication/ECT status in patients. 
4.6. Limitations of the study 
The results of the present study should be interpreted in light of 
several important limitations. 
First, the used parameters were determined in blood, and outcomes 
might differ from measurements in the brain or in the CSF. Of interest in 
this context is that McGuiness et al. (2016) showed that in the non-obese 
diabetic mouse model of anxiety and depression, inflammatory stimu-
lation with lipopolysaccharides (LPS) did induce the expression of ISGs 
and IDO-1 in the brain, but that it did not induce ISG expression in 
circulating monocytes (while it did induce ICCG expression in these cells, 
thus giving a monocyte profile similar to the pattern found here in pa-
tients). This shows that a different inflammatory reaction of the brain 
versus the periphery is possible and this thus also makes a local brain 
depletion of TRP due to a local IDO-1 overexpression possible in the 
absence of a similar reaction in the periphery. 
Furthermore, the inflammatory parameter used was the expression 
of inflammatory genes in circulating monocytes. We were only able to 
measure the circulating inflammatory compounds hsCRP and IL-6 in the 
Muenster patients and controls (Supplementary Table 4). Of note, we 
did not find significant elevations of these inflammatory compounds in 
patients, there did also not exist a positive correlation of these com-
pounds with the monocyte inflammatory gene state. The latter suggests 
other sources of these serum inflammatory compounds than the mono-
cytes (e.g. liver and adipose tissue). A similar discrepancy between 
monocyte inflammatory state and serum inflammatory serum com-
pounds has been described for the metabolic syndrome too, where 
adiposity and blood lipid levels play an important role in the discrep-
ancy (Baldeon-Rojas et al., 2016). Interestingly, KYN and QUIN serum 
levels did correlate to the serum levels of hsCRP and IL-6 (see legend 
Supplementary Table 4). All this is of relevance since various reports 
showed increased blood/CSF IL-6, KYN and QUIN levels in patients with 
MDD and suicidal behavior (Lindqvist et al., 2009; Sublette et al., 2011; 
Erhardt et al., 2013); high QUIN levels have also been detected in the 
microglia of suicide victims (Busse et al., 2015). Thus, the positive 
correlation between blood/CSF inflammatory compounds, QUIN, and 
KYN could highlight a detection possibility for an important subgroup of 
patients with MDD. Unfortunately, our information on patient’s risk for 
suicidal behavior was not uniformly recorded in the patients under study 
here, while psychotic patients were excluded from recruitment in the 
MOODINFLAME study. Therefore, we could not perform studies on the 
effects of these variables in this sample of patients with MDD and HCs. 
Also, and although we investigated a larger panel of TRP and KP 
metabolites than most of the previous studies, our panel is still limited. 
Future studies should consider other KP metabolites, such as 3-HAA 
and/or AA, as well as the genes for tryptophan hydroxylase (TPH)-II, 
monoamine oxidase (MAO), kynureninase and/or TDO. 
Another limitation was the relatively small sample size of the Munich 
cohort compared to the Muenster cohort, yet we have tried to take this 
into account in our supplementary material and pooled the data of the 
two cohorts to be able to draw more generalized conclusions for MDD, 
irrespective of the phase of the episode. We additionally analyzed in this 
total cohort medicated and medication-free patients,separately. 
Furthermore, methodologies for TRP metabolite determinations 
differed between both cohorts and unfortunately, various runs of assays 
were carried out on limited numbers of patients over time, resulting in 
the condition that not all variables were tested in all patients. To be able 
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to pool the data we harmonized data of a metabolite or immune 
parameter to the means of the HC value of that parameter, this 
harmonization had no effects on actual fold differences (and the sig-
nificance level) between patients and control values of that parameter. 
Nevertheless, future studies on larger cohorts should try to standardize 
as much as possible their detection assays and include larger groups of 
antidepressant-treated and antidepressant-naïve patients with MDD in 
better defined phases of the disease to obtain more precise data on TRP 
metabolism. 
5. Conclusions 
The systemic TRP/KYN catabolic pathway shows various activation 
and deactivation steps in MDD which are linked to the inflammatory 
state of patients. 
TRP serum levels were reduced in patients and linked to an increased 
pro-inflammatory (ICCGs) monocyte state. This was in particular 
evident in the subgroup of patients with the highest HAM-D 17 score 
(Munich patients). Contrary to what expected, KYN serum levels were 
not increased in patients; an increased KYN/TRP ratio was only found in 
the subgroup of patients with the lowest TRP serum levels (Munich 
patients). IDO-1 monocyte expression levels were decreased in patients 
and negatively related to their pro-inflammatory (ICCGs) monocyte 
state. Thus, a decrease in TRP serum levels via an ICCGs-inflammatory 
activation of the KP is unlikely in MDD. 
Downstream from KYN, various other activation and deactivation 
steps were detected, and linked to the inflammatory state of patients. 
This resulted, regarding compound capable of influencing glutamate 
receptors, in reduced serum levels of 3-HK (NMDA-R agonist), KYNA 
(NMDA-R antagonist), and XA (mGlu2/3 agonist). PIC (NMDA-R 
antagonist) was increased in patients, QUIN (NMDA-R agonist) was 
decreased only in the Muenster patients. Only 3-HK serum levels were 
related to the pro-inflammatory (ICCGs) monocyte state of patients; the 
deactivation of the KYN to 3-HK breakdown pathway was in particular 
evident in the cohort of patients with the highest HAM-D 17 score 
(Munich patients). The ultimate effect on brain glutamate receptor 
triggering of this altered equilibrium between peripheral agonists and 
antagonists needs further exploration. 
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